UNITED STATES SECURITIES AND EXCHANGE COMMISSION Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2024 Commission File Number: 001-39481 PainReform Ltd. (Translation of registrant's name into English) 65 Yigal Alon St., Tel Aviv 6744316 Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Washington, D.C. 2 ...

Core Insights - PainReform Ltd. announced positive findings regarding the compatibility of its lead product PRF-110 with surgical sutures in human clinical trials, indicating its potential for extended, non-opiate post-surgical pain relief [1][4] Group 1: Product and Clinical Trials - PRF-110 is designed to provide extended post-surgical pain relief without the use of opiates, utilizing a proprietary extended-release drug-delivery system [5] - Comprehensive in vitro studies were conducted to assess the impact of PRF-110 on both nonabsorbable (PROLENE™) and resorbable (Vicryl™) sutures, focusing on mechanical properties such as breaking force and elongation [2] - Results showed that PRF-110 does not affect the mechanical properties of either type of suture, suggesting compatibility with surgical conditions [3] Group 2: Company Leadership and Future Directions - Ehud Geller, Chairman and interim CEO, emphasized the importance of these findings as a milestone for the safety and efficacy of PRF-110, advancing the product toward commercialization [4] - The ability to provide extended pain relief without compromising suture integrity is highlighted as a significant advancement in post-surgical care [4]

Core Viewpoint - PainReform Ltd. has entered into definitive agreements for the immediate exercise of outstanding warrants, allowing the purchase of up to 989,300 ordinary shares at a reduced exercise price of $1.60 per share, down from $4.80 per share [1][2]. Group 1: Financial Details - The gross proceeds from the exercise of the warrants are expected to be approximately $1.58 million, prior to deducting placement agent fees and estimated offering expenses [3]. - The company intends to use the net proceeds from the offering for general corporate purposes [3]. Group 2: New Warrants - In exchange for the immediate exercise of the warrants, the company will issue new unregistered warrants to purchase up to 1,978,600 ordinary shares, with an exercise price of $1.60 per share, exercisable immediately upon issuance and expiring five years from the date of issuance [2]. Group 3: Regulatory Information - The new warrants were offered in a private placement and have not been registered under the Securities Act of 1933, meaning they cannot be offered or sold in the U.S. without registration or an applicable exemption [4]. - The company has agreed to file a registration statement with the SEC covering the resale of the ordinary shares issuable upon exercise of the new warrants [4]. Group 4: Company Overview - PainReform is a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics, with its lead product PRF-110 targeting postoperative pain relief [6]. - PRF-110 is based on the local anesthetic ropivacaine and is designed to provide localized and extended postoperative analgesia without the need for repeated doses [6].

Exhibit 99.1 PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX | | Page | | --- | --- | | Condensed Balance Sheets | F-2 | | Condensed Statements of Comprehensive Loss | F-3 | | Condensed Statements of Changes in Shareholders' (Deficit) Equity | F-4 | | Condensed Statements of Cash Flows | F-5 | | Notes to Condensed Financial Statements | F-6 - F-12 | PAINREFORM LTD. CONDENSED BALANCE SHEETS (Unaudited) U.S. dollars in thousands U.S. dollars in thou ...

TEL AVIV, Israel, Aug. 07, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced compelling safety data for its lead product candidate, PRF-110. This data, derived from pharmacokinetic (PK) studies in both herniorrhaphy and bunionectomy clinical trials, highlights PRF-110's promising safety profile, with maximum blood levels (Cmax) recorded at approxi ...

TEL AVIV, Israel, Aug. 01, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, announces a major advancement in the development of its lead asset, PRF-110. The Company's new highly scalable manufacturing process, for which it recently filed a new patent, has enabled PRF-110 to achieve full product stability for 18 months at room temperature. This stability study is ...

TEL AVIV, Israel, July 24, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced it has filed a patent covering its new and highly scalable manufacturing process for PRF-110, its flagship product designed to revolutionize post-operative pain control. The patent filing follows successful completion and testing of the new process. This milestone not only ...

TEL AVIV, Israel, June 26, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced a major milestone on the way to registration - the successful completion of patient enrollment in its Phase 3 clinical trial for PRF-110, a novel analgesic drug candidate designed for the treatment of post-operative pain. In total, 428 patients have been enrolled at eight ...

TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that the Company received a letter from the Nasdaq Listing Qualifications (the "Letter"), indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to ...

Exhibit 99.1 PAINREFORM LTD. CONDENSED FINANCIAL STATEMENTS AS OF MARCH 31, 2024 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX | | Page | | --- | --- | | Condensed Balance Sheets | F-2 | | Condensed Statements of Comprehensive Loss | F-3 | | Condensed Statements of Changes in Shareholders' Equity | F-4 | | Condensed Statements of Cash Flows | F-5 | | Notes to Condensed Financial Statements | F-6 - F-10 | PAINREFORM LTD. CONDENSED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) U.S. dollars in thousands (except sha ...